Nanoenabled smart drug delivery in One Health: advances in targeted therapy and theranostics

Read full text
Authors: Olalekan John Okesanya, Uthman Okikiola Adebayo, Lawal Akorede Habeeb, Ahishakiye Gilbert, Md Faiazul Haque Lamem, Mohamed Mustaf Ahmed, Tolutope Adebimpe Oso, Don Eliseo Lucero-Prisno
Cited by: 2
References: 105

Abstract

Abstract Vector-borne and zoonotic diseases (VBZDs) remain a critical global health challenge, disproportionately affecting low- and middle-income countries and driving significant morbidity, mortality, and economic loss. This review synthesizes emerging evidence on nano-enabled smart drug delivery system (SDDS) within the One Health framework, emphasizing their role in advancing targeted therapy, controlled release, and theranostics for VBZD management. Nano-enabled platforms such as liposomes, polymeric nanoparticles, nanogels, metal–organic frameworks, and biomimetic carriers are designed for stimuli-responsive and site-specific delivery, enhancing therapeutic precision, lowering dosing frequency, and reducing the risk of drug resistance. Controlled-release formulations of agents such as artemisinin derivatives, amphotericin B, and ivermectin have demonstrated superior efficacy in the treatment of malaria and leishmaniasis, and in vector control applications. Targeted delivery strategies extend beyond human therapies to address viral reservoirs, infected macrophages, and arthropod vectors, highlighting the cross-species applications central to One Health. Theranostic innovations combine imaging and therapy to enable early disease detection, real-time monitoring, and the design of adaptive treatment strategies. Applications span human, animal, and environmental domains, from nanovaccines and veterinary antimicrobials to nanoparticle-based larvicides and biosensors for vector surveillance. Future directions underscore the integration of AI-driven nanodesign, scalable and eco-friendly synthesis, and harmonized regulatory frameworks to increase accessibility in resource-limited settings. Although clinical trials are limited, ongoing translational efforts indicate the transformative potential of nanomedicine in VBZD control. Ultimately, integrating nano-enabled SDDS into a One Health framework provides a sustainable and collaborative approach to reduce the global burden of zoonotic and vector-borne diseases.

Fields of Study & Subjects

Parasitic Diseases Research and Treatment Malaria Research and Control Research on Leishmaniasis Studies

Publication details

Journal / source
One Health Advances
Publisher
Springer Science and Business Media LLC
Volume
4
Issue
1
Publication date
4 February 2026
Language
EN